Navigation Links
MMX in Medical News

Santarus to Webcast Analyst Day and Investor Briefing Presentation on May 13

...ent, Commercial Operations, Santarus, Inc. mmx (R) Technology - The Benefits of Targeted Deliv...rohn's and Colitis Organization Budesonide mmx (R) - Clinical Development Program in Ulcerative ...g Center for Travelers' Health Rifamycin SV mmx (R) - Clinical Development Program in Traveler'...

Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients With Ulcerative Colitis Published in Leading GI Journal

...y ulcerative colitis treatment that utilizes MMX(R) Technology. Lialda with mmx Technology combines a pH dependent gastro-resistant coating, which delays t...ialization rights in Italy. Cosmo Pharmaceuticals SpA, Milan, developed the mmx technology. For further information please contact: Investor Relatio...

Shire Launches Patient Education Forums on Better Managing the Challenges of Ulcerative Colitis

...y ulcerative colitis treatment that utilizes MMX(R) Technology. LIALDA with mmx Technology combines a pH dependent gastro-resistant coating, which delays t...ialization rights in Italy. Cosmo Pharmaceuticals SpA, Milan, developed the mmx technology. Important Safety Information for LIALDA LIALDA tablets are ...

Nationwide Survey Reveals Differing Physician and Patient Perceptions Regarding Impact of Ulcerative Colitis on Patients' Lives

...tment that utilizes MMX(R) Technology. LIALDA with mmx Technology combines a pH dependent gastro-resistan...y. Cosmo Pharmaceuticals SpA, Milan, developed the mmx technology. Important Safety Information for LIA...ani and Shire Pharmaceuticals. Cosmo's proprietary mmx technology is at the core of the company's product...

LIALDA demonstrates prolonged release of mesalamine in an in vitro study using a simulated colon

...on, with a tablet core containing mesalamine with hydrophilic and lipophilic excipients. LIALDA is the only ulcerative colitis treatment that utilizes mmx Technology. In two pivotal phase III clinical studies, LIALDA was shown to be superior to placebo in inducing remission and treating the symptoms ...
MMX in Medical Technology

Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea

-- Primary endpoint achieved -- LAINATE, Italy - July 4, 2007 - Cosmo Pharmaceuticals SpA (SWX:COPN) announced today positive preliminary results from its phase II/III study with CB-01-11 (Rifamycin SV MMX(tm)) in infectious diarrhoea. CB-01-11 is a broad spectrum, semi-synthetic antibiotic that...

Analysis of Ulcerative Colitis (UC) Time to Symptom Resolution Data from Pivotal Study of LIALDA(TM) (mesalamine) Presented at DDW

...y ulcerative colitis treatment that utilizes MMX(R) Technology. LIALDA with mmx Technology combines a pH dependent gastro-resistant coating, which delays t...ialization rights in Italy. Cosmo Pharmaceuticals SpA, Milan, developed the mmx technology. SHIRE PLC Shire's strategic goal is to become the leading s...

New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG

...tment that utilizes MMX(R) Technology. LIALDA with mmx Technology combines a pH dependent gastro-resistan...y. Cosmo Pharmaceuticals SpA, Milan, developed the mmx Technology. For more information about LIALDA and...ani and Shire Pharmaceuticals. Cosmo's proprietary mmx Technology is at the core of the company's product...

Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many Aspects of Daily Life

...new formulation in this class to be approved since 2000. LIALDA is the only ulcerative colitis treatment that utilizes MMX(TM) Technology. LIALDA with mmx Technology combines a pH dependent gastro-resistant coating, which delays the release of the medication to the colon (the site of the inflammation in ...

Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term Safety Study of Lialda (mesalamine) Presented at DDW

...new formulation in this class to be approved since 2000. LIALDA is the only ulcerative colitis treatment that utilizes MMX(TM) Technology. LIALDA with mmx Technology combines a pH dependent gastro-resistant coating, which delays the release of the medication to the colon (the site of the inflammation in ...
MMX in Biological Technology

Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis

...ally the patient population who may benefit most." Once-daily LIALDA with mmx technology contains the highest mesalamine dose per tablet (1.2 g), so pati...ialisation rights in Italy. Cosmo Pharmaceuticals SpA, Milan, developed the mmx technology. For more information about LIALDA and for Full Prescribing In...
Other Tags
(Date:5/25/2013)... Actos lawsuit claims pending ... Court, Western District of Louisiana, continue to move forward, ... Management Order issued on May 21st, the Court has ... in the Actos bladder cancer litigation, as well as ... Liability Litigation, MDL No. 2299) , “We continue to ...
(Date:5/25/2013)... 25, 2013 Radius Engineering International ... company in the US and has been building ... over 35 years. M.E. and President, Walton McCarthy, ... NBC Weapon Fundamentals and Shelter Engineering Standards, Sixth ... on shelter engineering. McCarthy is considered the leading ...
(Date:5/25/2013)... On May 20, 2013 the Sydney Morning Herald ... or plan for their eventual demise, but it is an ... Must-Do List to help people properly arrange for their last ... fact sheet.” , While not a formal document, this document ... It may include a summary of assets, debts, obtained ...
(Date:5/25/2013)... 25, 2013 On May 25, Voices ... research and advocacy, comments on a new study by ... incorporating cold atmospheric plasma into brain cancer treatment may ... to a Science Daily article, physicists from ... and physicians demonstrated the “synergistic effect of cold atmospheric ...
(Date:5/25/2013)... 25, 2013 According to world-renowned scholars, ... and powerful women that ever lived. Cleopatra’s legendary beauty ... of the most powerful men in her time. Cleopatra ... to keep her skin glowing and fresh, from her ... wax, maringa oil and cyprus grass. , Cleopatra was ...
Breaking Medicine News(10 mins):Health News:Actos Lawsuit News: Bernstein Liebhard LLP Notes New Case Management Order in Federal Actos Bladder Cancer Litigation 2Health News:Actos Lawsuit News: Bernstein Liebhard LLP Notes New Case Management Order in Federal Actos Bladder Cancer Litigation 3Health News:Radius Engineering International Inc. Offers Tools to Stay Safe and Recover From Any Disaster 2Health News:Radius Engineering International Inc. Offers Tools to Stay Safe and Recover From Any Disaster 3Health News:FuneralFinancials.com Releases Last Wishes Must-Do List 2Health News:Voices Against Brain Cancer Comments on Study that Shows Cold Plasma’s Success Against Brain Cancer Cells 2Health News:The Cleopatra Lift - A New Non Surgical Option to Aging Offered by Vancouver Physician 2Health News:The Cleopatra Lift - A New Non Surgical Option to Aging Offered by Vancouver Physician 3
(Date:5/22/2013)... also conclude that the 20 percent reduction in ... versus chest X-ray (CXR) screening previously reported in ... screening centers in the United States. , Philadelphia, ... patients about the benefits and risks of LDCT ... New England Journal of Medicine of ...
(Date:5/22/2013)... major new effort to educate the public and decision ... clean water that looms ahead in the 21st century. ... current edition of Chemical & Engineering News , ... the world,s largest scientific society. , Bassam Z. Shakhashiri, ... Ph.D., explain that shortages of reliable supplies of fresh ...
(Date:5/22/2013)... health effects from disposal of millions of rechargeable ... recommend stronger government policies to encourage recovery, recycling ... the conclusion of a new paper in the ... , Oladele A. Ogunseitan and colleagues point out ... everything from smart phones to components in new ...
Breaking Biology News(10 mins):NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 3
Other Contents